June 28th 2024
Dive in and learn more about the answers to yesterday’s quiz.
June 27th 2024
Test your knowledge of migraine therapies.
June 24th 2024
Check out these top featured stories from Drug Topics in June 2024.
June 19th 2024
A poster presented at AHS 2024 found that older patients tended to have more vitamin deficiencies compared to younger patients.
June 14th 2024
Academic, corporate, and clinical institutions must empower pharmacists to deliver informed and compassionate care to LGBTQ individuals that matches the standard received by their heterosexual and cisgender peers.
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Slideshow: Exploring Cannabis Utilization in the Oncology Landscape
Four abstracts presented at ASCO 2024 delved into cannabis and pain management, potential medication interactions, and symptom mitigation, in patients with cancer.
Check Your Work: Understanding Headache Types
Quiz: Understanding Headache Types
Test your knowledge different headache types.
Migraine and Headache Awareness Month: Resources Roundup
Check out this list of resources to share with patients who are managing a migraine or other headache diagnosis.
FDA Warns Consumers About Unapproved, Misbranded OTC Analgesic Products
The agency issued warning letters to 6 companies manufacturing these products.
Consumer Survey Data Show Opportunity, Challenges in OTC Space
The average US household spent $645 on OTC products in 2022.
Telehealth-Based OUD Treatment May Lead to Better Health, Obstetric Outcomes Among Pregnant Patients
Telehealth mitigates barriers like stigma, fear, and legal concerns associated with receiving opioid use disorder (OUD) care by offering a convenient and discreet treatment option.
Interventional Techniques Can Help Manage Pain in Patients With Cancer
With growing concerns around opioid use disorder, interventional pain management for patients with cancer can provide effective relief without the side effects associated with medication.
Complementary Health Approaches for Pain Management Increasing in Popularity
Complementary health approaches, like yoga or acupuncture, can be particularly appealing to patients seeking natural and non-invasive approaches to improve their health.
2023 New Drug Approvals: Part 2
Rural Patients Utilize ED for Migraine at Higher Rates
These populations are also more likely to receive opioid analgesic therapies.
The Unintended Impact of Opioid Prescribing Guidelines: Part 1
The CDC first released opioid prescribing guidelines in 2016.
Liposomal Bupivacaine Reduced Opioid Consumption Following Cesarean Section, Poster Says
A poster from ASHP Midyear 2023 demonstrated the effectiveness of liposomal bupivacaine as it is used for cesarean section procedures, regarded as an area with increasing utilization.
Slideshow: Evaluating Perioperative Opioid Use and Analgesic Options
Three poster presented at the ASHP Midyear Clinical Meeting delved deeper into perioperative pain management.
In the Opioid Epidemic, Treatment Challenges Still Persist
Despite societal need, stigma around MAT and MOUD still exists.
Topical Analgesics: A New Frontier for First-Line Pain Management
Despite a wealth of data proving their efficacy for acute and chronic pain, these products remain underutilized in the United States.
OTC Products, Oral Prescriptions Demonstrate Efficacy in Episodic Migraine
Although there were some differences in response after dosing, both OTC and oral prescriptions demonstrated statistically significant improvements in pain.
Handle With Care: Dispensing Controlled Substances in the Pharmacy
Filling a prescription for a controlled substance requires more oversight than the average prescription.
Intranasal CGRP Antagonist Is Approved for the Treatment of Acute Migraines
Zavegepant joins other CGRP antagonists as an option for individuals experiencing migraine.
Pharmacists Role in Opioid Stewardship, Perioperative Main Management Crucial
Prescribing Alert Increases Rates of Naloxone, Opioid Co-Prescriptions
The alert was implemented after passage of a state senate bill.
CGRP Inhibitors Significantly Reduce Disability in Migraine
Study results add to the body of evidence demonstrating the efficacy of CGRP inhibitors for migraine treatment and prophylaxis.
FDA Approves Buprenorphine Extended-Release Subcutaneous Injection for OUD
This treatment is the first and only long-acting buprenorphine injectable with weekly and monthly doses.
Majority of Antidepressants Used for Treatment of Chronic Pain Lack Sufficient Efficacy, Safety Data
A new meta-analysis found duloxetine to be the only commonly prescribed medication that was effective.
FDA Approves Expanded Indication for Atogepant for Prevention of Chronic Migraine
Only the 60 mg dose of atogepant is approved for chronic migraine prevention.
Age, Food Security, And Financial Situation All Common Factors in OUD Cases
A new study from JAPHA explores the link between OUD and social factors.
Breaking: FDA Approves OTC Designation for Naloxone Nasal Spray
Naloxone hydrochloride nasal spray (Narcan) 4 mg is expected to be available over the counter in late summer 2023.
How Vitamin D Can Help Migraines In Young Patients
Vitamin D supplementation may be an effective and safe adjunctive prophylactic therapy to topiramate for children who experience migraine attacks, showed a study conducted in Saudi Arabia.
FDA Clears First Commercially Available Blood Test to Evaluate for TBI, Concussion
The test is intended to complement the company’s TBI plasma test, which received FDA clearance in 2021.
FDA: Nerivio Cleared for Migraine Prevention
Nerivio received clearance in January 2021 for use in acute migraine.